{"denoms":[{"counts":[{"groupId":"BG000","value":"13"}],"units":"Participants"}],"groups":[{"description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","id":"BG000","title":"Treatment (Pembrolizumab)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"59","upperLimit":"71","value":"68"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"11.95","upperLimit":"13.95","value":"12.4"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.8","upperLimit":"3.15","value":"1.9"}]}],"title":"Serum paraprotein"}],"description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related labs","unitOfMeasure":"gm/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"8.7","upperLimit":"9.55","value":"9.3"}]}],"title":"Calcium"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.79","upperLimit":"1.04","value":".88"}]}],"title":"Creatinine"}],"description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related labs","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.75","upperLimit":"2.3","value":"1.9"}]}],"title":"B2 microglobulin"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18.18","upperLimit":"277.48","value":"127.04"}]}],"title":"Kappa free light chain"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6.74","upperLimit":"14.59","value":"8.08"}]}],"title":"Lambda free light chain"}],"description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related labs","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"349.5","upperLimit":"488","value":"439"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related lab Lactate dehydrogenase","unitOfMeasure":"u/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"17.5","upperLimit":"45","value":"30"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related lab Bone marrow biopsy plasma cells","unitOfMeasure":"percentage of plasma cells"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"30.5","value":"6"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related lab Bence Jones urine protein","unitOfMeasure":"mg/day"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2.44","upperLimit":"38.25","value":"12.27"}]}],"title":"Free Light Chains (FLCs) ratio"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6.44","upperLimit":"38.25","value":"17.95"}]}],"title":"Involved:Uninvolved ratio"}],"description":"Measure Description: Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Myeloma related labs","unitOfMeasure":"ratio"}]}